| Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. | |
| | |
MedLine Citation:
|
PMID: 9373264 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Following reports of childhood acute myeloid leukemia (AML) showing that patients with t(9; 11)(p22; q23) have a better prognosis than those with translocations between 11q23 and other chromosomes, we compared response to therapy and survival of 24 adult de novo AML patients with t(9; 11) with those of 23 patients with other 11q23 translocations [t(11q23)]. Apart from a higher proportion of French-American-British (FAB) M5 subtype in the t(9; 11) group (83% v 43%, P = .006), the patients with t(9; 11) did not differ significantly from patients with t(11q23) in terms of their presenting clinical or hematologic features. Patients with t(9; 11) more frequently had an extra chromosome(s) 8 or 8q as secondary abnormalities (46% v 9%, P = .008). All patients received standard cytarabine and daunorubicin induction therapy, and most of them also received cytarabine-based intensification treatment. Two patients, both with t(9; 11), underwent bone marrow transplantation (BMT) in first complete remission (CR). Nineteen patients (79%) with t(9; 11) and 13 (57%) with t(11q23) achieved a CR (P = .13). The clinical outcome of patients with t(9; 11) was significantly better: the median CR duration was 10.7 versus 8.9 months (P = .02), median event-free survival was 6.2 versus 2.2 months (P = .009), and median survival was 13.2 versus 7.7 months (P = .009). All patients with t(11q23) have died, whereas seven (29%) patients with t(9; 11) remain alive in first CR. Seven of eight patients with t(9; 11) who received postremission regimens with cytarabine at a dose of 100 (four patients) or 400 mg/m2 (2 patients) or who did not receive postremission therapy (2 patients) have relapsed. In contrast, 7 (64%) of 11 patients who received intensive postremission chemotherapy with high-dose cytarabine (at a dose 3 g/m2) (5 patients), or underwent BMT (2 patients) remain in continuous CR. We conclude that the outcome of adults with de novo AML and t(9; 11) is more favorable than that of adults with other 11q23 translocations; this is especially true for t(9; 11) patients who receive intensive postremission therapy. |
| | |
Authors:
|
K Mrózek; K Heinonen; D Lawrence; A J Carroll; P R Koduru; K W Rao; M P Strout; R E Hutchison; J O Moore; R J Mayer; C A Schiffer; C D Bloomfield |
Related Documents
:
|
14584754 - Erythropoietic activities in acute leukemia and in malignant lymphoma with or without b... 10589074 - Acid-base and electrolyte abnormalities in patients with acute leukemia. 53444 - A clinical service for prenatal diagnosis. 9063374 - Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation t... 20561984 - Study of chromosomal region 5p13.1 in crohn's disease, ulcerative colitis, and rheumato... 12379404 - Platelet-monocyte aggregates in patients with chronic venous insufficiency remain eleva... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Blood Volume: 90 ISSN: 0006-4971 ISO Abbreviation: Blood Publication Date: 1997 Dec |
Date Detail:
|
Created Date: 1997-12-23 Completed Date: 1997-12-23 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 7603509 Medline TA: Blood Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 4532-8 Citation Subset: AIM; IM |
Affiliation:
|
Roswell Park Cancer Institute, Buffalo, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Adult Chromosome Aberrations Chromosomes, Human, Pair 11* Chromosomes, Human, Pair 8 Chromosomes, Human, Pair 9* DNA-Binding Proteins / genetics Humans Leukemia, Myeloid / genetics*, physiopathology, therapy Myeloid-Lymphoid Leukemia Protein Proto-Oncogenes* Remission Induction Transcription Factors* Translocation, Genetic* Treatment Outcome Zinc Fingers |
| Grant Support | |
ID/Acronym/Agency:
|
CA35279/CA/NCI NIH HHS; CA37027/CA/NCI NIH HHS; CA47545/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/DNA-Binding Proteins; 0/MLL protein, human; 0/Transcription Factors; 149025-06-9/Myeloid-Lymphoid Leukemia Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Next Document: Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to f...